Nearly 30% of the funding poured into healthcare startups last year, including for biotechs, went to companies leveraging ...

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...

Barré syndrome, although it said data don’t prove a causal link and affirmed the shots’ benefit outweighs their risks.

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...

Peoria, IL, Jan 8, 2025 — Veloxity Labs, a bioanalytical contract research organization (CRO) specializing in accelerating ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle ...

January 7th, 2025 – Bioforum, The Data Masters, a leading global clinical research organization (CRO) specializing in ...